Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients

Haemophilia

Volumn 20, Issue 1, 2014, Pages 99-105

  Williams, M ^a   Will, A ^b   Stenmo, C ^c   Rosholm, A ^c   Tehranchi, R ^c  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Children; Congenital FXIII deficiency; Pharmacokinetics; Prophylaxis; Recombinant FXIII; Safety

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13A;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SINGLE DRUG DOSE; STEADY STATE; YOUNG ADULT;

CHILDREN; CONGENITAL FXIII DEFICIENCY; PHARMACOKINETICS; PROPHYLAXIS; RECOMBINANT FXIII; SAFETY;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FACTOR XIII; FACTOR XIII DEFICIENCY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890860738     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12224     Document Type: Article

References (15)

1. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95: 362-70.
2. Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14: 1190-200.
3. Peyvandi F, Cattaneo M, Inbal A, De Moerloose P, Spreafico M. Rare bleeding disorders. Haemophilia 2008; 14(Suppl. 3): 202-10.
4. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-84.
5. Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol 1998; 5: 372-5.
6. Brackmann HH, Egbring R, Ferster A et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74: 622-5.
7. Rodeghiero F, Tosetto A, Di Bona E, Castaman G. Clinical pharmacokinetics of a placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency. Am J Hematol 1991; 36: 30-4.
8. Lovejoy AE, Reynolds TC, Visich JE et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
9. Reynolds TC, Butine MD, Visich JE et al. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. J Thromb Haemost 2005; 3: 922-8.
10. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe, and novel treatment for congenital factor XIII deficiency. Blood 2012; 119: 5111-7.
11. Björkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-8.
12. Peyvandi F, Palla R, Menegatti M et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10: 615-21.
13. Björkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-98.
14. Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
15. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671-84.